VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LGVN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LGVNLongeveron Inc.
$1.92$6M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLGVNBalance Sheet

Longeveron Inc. (LGVN) Balance Sheet

8Y historyFree accessUpdated daily

The company's financial position is increasingly vulnerable, with total assets contracting from $29.9M in 2024Q3 to $21.2M in 2026Q1, while retained earnings have deteriorated to -$137.0M.

Income StatementBalance SheetCash FlowRatios

LGVN Balance Sheet

Annual statement

LGVN Balance Sheet

Longeveron Inc. (LGVN) balance sheet — 8-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets8.15M5.45M19.62M5.85M20.28M35.38M1.85M2.37M4.16M
Cash & Short-Term Investments7.25M4.66M19.23M5.36M19.66M35.04M816K1.87M4.03M
Cash Only7.25M4.66M19.23M4.95M10.5M25.66M816K1.87M4.03M
Short-Term Investments000412K9.15M9.38M000
Accounts Receivable64K104K84K111K218K55K420K451.46K0
Days Sales Outstanding23.5831.6612.8257.1465.1115.3727.2329.27-
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets0686K308K376K404K0561K00
Total Non-Current Assets3.87M4.81M5.93M6.23M7.13M7.39M7.39M8.21M6.36M
Property, Plant & Equipment1.69M2.35M3.33M3.75M4.48M4.88M5.67M6.48M4.76M
Fixed Asset Turnover0.60x0.51x0.72x0.19x0.27x0.27x0.99x0.87x0.45x
Goodwill000000000
Intangible Assets2.17M2.29M2.4M2.29M2.41M2.33M1.55M1.48M1.35M
Long-Term Investments100K100K0000000
Other Non-Current Assets8K76K202K193K244K177K177K250.89K250.89K
Total Assets12.02M10.26M25.56M12.08M27.41M42.77M9.24M10.58M10.52M
Asset Turnover0.08x0.12x0.09x0.06x0.04x0.03x0.61x0.53x0.20x
Asset Growth %-88.42%-59.85%111.61%-55.94%-35.9%362.84%-12.7%0.6%-
Total Current Liabilities6.53M4.09M2.58M3.89M4.87M2.71M3.83M2.49M1.86M
Accounts Payable1.96M423K99K638K1.75M645K1.59M1.15M1.21M
Days Payables Outstanding772.47389.8971.13477.19881.54328.81152.6110.82302.57
Short-Term Debt0655K0000177K00
Deferred Revenue (Current)222K40K40K506K506K199K10K541.79K405K
Other Current Liabilities02.97M001.4M000209.26K
Current Ratio1.25x1.33x7.60x1.50x4.17x13.06x0.48x0.95x2.24x
Quick Ratio1.25x1.33x7.60x1.50x4.17x13.06x0.48x0.95x2.24x
Cash Conversion Cycle-748.9--------
Total Non-Current Liabilities778K499K1.09M1.45M2.04M2.6M3.45M3.65M1.84M
Long-Term Debt000000311K00
Capital Lease Obligations229K169K824K1.45M2.04M2.6M3.14M3.65M0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities778K330K265K000001.84M
Total Liabilities7.3M4.59M3.67M5.34M6.91M5.31M7.28M6.14M3.71M
Total Debt412K824K1.45M2.04M2.6M3.14M4.14M4.14M0
Net Debt-6.83M-3.84M-17.79M-2.91M-7.9M-22.52M3.33M2.27M-4.03M
Debt / Equity0.09x0.15x0.07x0.30x0.13x0.08x2.12x0.93x-
Debt / EBITDA-0.02x--------
Net Debt / EBITDA0.30x--------
Interest Coverage------4260.25x-567.80x-21977.91x-
Total Equity4.71M5.67M21.89M6.74M20.5M37.45M1.96M4.45M6.81M
Equity Growth %-151.21%-74.07%224.68%-67.12%-45.26%1813.8%-55.97%-34.77%-
Book Value per Share1.473.2314.7031.0197.78198.0111.6127.7542.84
Total Shareholders' Equity4.71M5.67M21.89M6.74M20.5M37.45M1.96M4.45M6.81M
Common Stock3K22K14K2K21K21K1.96M07.11M
Retained Earnings-149.25M-132.31M-109.61M-84.98M-62.77M-43.94M000
Treasury Stock000000000
Accumulated OCI0000-357K000-1.39M
Minority Interest000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Eroding Capital Base Signals Vulnerability

As reported in recent financial statements, Longeveron's total assets have declined from a peak of $29.9M in 2024Q3 to $21.2M in 2026Q1, reflecting a persistent consumption of capital that underscores the company's precarious position as it attempts to advance its clinical pipeline without commercial revenue.

The consistent contraction in total assets suggests that the company is depleting its primary resources to fund ongoing R&D activities. This downward trajectory in asset value, coupled with the lack of offsetting revenue growth, implies that the current business model is unsustainable without frequent external capital injections.

Cash Runway Constraints Demand Attention

Based on the provided quarterly data, cash and equivalents plummeted from $22.8M in 2024Q3 to $15.8M in 2026Q1, with the current ratio fluctuating significantly, indicating that the company's ability to cover short-term obligations is increasingly dependent on the timing of external financing rather than operational cash generation.

The volatility in the current ratio, which dropped as low as 0.71 in 2024Q1, highlights a recurring liquidity risk that investors should monitor closely. The rapid depletion of cash reserves suggests that the company may face a critical funding gap in the near term, potentially necessitating dilutive equity raises.

Accumulated Deficits Weigh on Equity

According to historical balance sheet data, retained earnings have deteriorated to -$137.0M as of 2026Q1, a trend that reflects the substantial and persistent losses incurred by the company while attempting to commercialize its proprietary cell therapy platform through high-cost clinical trials.

The deep negative balance in retained earnings is a clear indicator of the significant capital required to sustain the company's research-heavy business model. This erosion of equity quality suggests that shareholders are bearing the full brunt of the company's pre-commercial status, with little prospect for near-term value creation.

Intangible Asset Valuation Risks Persist

As indicated by the balance sheet, goodwill remains relatively stable at $2.2M, which warrants further investigation as it represents a non-trivial portion of total assets that could be subject to impairment if clinical trial outcomes for LOMECEL-B fail to meet regulatory or market expectations.

While the goodwill figure appears modest, its presence on the balance sheet for a clinical-stage biotech firm is a potential distortion that may mask the true economic value of the company's assets. Investors should consider the risk that these intangible assets may not provide the expected future economic benefits.

LGVN — Frequently Asked Questions

Quick answers to the most common questions about buying LGVN stock.

What are the total assets of Longeveron Inc. (LGVN)?

As of 2025, Longeveron Inc. (LGVN) had total assets of $10.3M including $5.5M in current assets.

How much debt does Longeveron Inc. (LGVN) have?

Longeveron Inc. (LGVN) carries total debt of $0.8M, offset by $4.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Longeveron Inc.?

Longeveron Inc. (LGVN) has total shareholders' equity (book value) of $5.7M ($3.23 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Longeveron Inc.'s current ratio and liquidity?

Longeveron Inc. (LGVN) reported a current ratio of 1.33x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.